Sugi Predict

Sugi Predict / Targets / PSMD12

PSMD12

26S proteasome non-ATPase regulatory subunit 12 · O00232 · PSMD12 on Sugi Atlas →

8,273 patent compounds predicted against PSMD12, 6,558 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to PSMD12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Study of Constitutional Platelet Disease nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMD12 binder may also engage these)

ProteinNameSimilarity
Q5RBI3 — 1.000 Q5RBI3 →
Q2KJ25 — 1.000 Q2KJ25 →
Q9D8W5 — 0.997 Q9D8W5 →
Q9V345 — 0.982 Q9V345 →
Q5R882 — 0.977 Q5R882 →
Q5E993 — 0.977 Q5E993 →
Q7KLV9 — 0.975 Q7KLV9 →
A7RWP6 — 0.975 A7RWP6 →
Q8W207 — 0.974 Q8W207 →
Q9CRD2 — 0.973 Q9CRD2 →
Q9LNU4 — 0.973 Q9LNU4 →
B0BNG0 — 0.973 B0BNG0 →
Q6TGY8 — 0.972 Q6TGY8 →
EMC2 ER membrane protein complex subunit 2 0.971 landscape →
Q9LQR8 — 0.971 Q9LQR8 →
Q9SV20 — 0.970 Q9SV20 →
Q9SV21 — 0.969 Q9SV21 →
P93768 — 0.969 P93768 →
Q66HV4 — 0.969 Q66HV4 →
Q7QG73 — 0.969 Q7QG73 →
Q5R922 — 0.968 Q5R922 →
P45432 — 0.968 P45432 →
D2SW95 — 0.967 D2SW95 →
Q3B8M3 — 0.967 Q3B8M3 →
Q6H8D6 — 0.967 Q6H8D6 →
Q8RWF0 — 0.966 Q8RWF0 →
Q5ZIA5 — 0.966 Q5ZIA5 →
Q3UGF1 — 0.966 Q3UGF1 →
P91926 — 0.966 P91926 →
A0JN39 — 0.966 A0JN39 →